Martin Capital Advisors LLP Acquires 128 Shares of Edwards Lifesciences Co. (NYSE:EW)

Martin Capital Advisors LLP boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,490 shares of the medical research company’s stock after purchasing an additional 128 shares during the period. Edwards Lifesciences comprises about 1.6% of Martin Capital Advisors LLP’s portfolio, making the stock its 19th largest holding. Martin Capital Advisors LLP’s holdings in Edwards Lifesciences were worth $1,944,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. Sequoia Financial Advisors LLC increased its stake in shares of Edwards Lifesciences by 11.4% during the first quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock worth $1,081,000 after purchasing an additional 941 shares during the period. Zions Bancorporation N.A. boosted its position in shares of Edwards Lifesciences by 34.7% in the first quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 448 shares during the period. Covestor Ltd grew its stake in shares of Edwards Lifesciences by 18.2% in the first quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 188 shares in the last quarter. Mather Group LLC. increased its position in Edwards Lifesciences by 53.5% during the first quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock worth $846,000 after acquiring an additional 2,503 shares during the period. Finally, Mackenzie Financial Corp raised its stake in Edwards Lifesciences by 3.1% in the 1st quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock worth $77,173,000 after purchasing an additional 19,798 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EW. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday. Evercore ISI raised their price target on Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Finally, StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Edwards Lifesciences Trading Down 0.6 %

NYSE EW traded down $0.51 during trading on Friday, hitting $85.94. The company had a trading volume of 3,870,655 shares, compared to its average volume of 3,865,306. The company’s fifty day moving average is $90.14 and its 200-day moving average is $78.19. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The company has a market cap of $51.73 billion, a price-to-earnings ratio of 37.37, a price-to-earnings-growth ratio of 4.32 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the firm posted $0.64 EPS. The business’s revenue was up 13.3% on a year-over-year basis. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.